Authors:
Daniel Ng, PharmD, MBA, Senior Director, Head of HEOR, International Markets and Greater China, Astellas Pharma Global Development, Astellas
Hidecki Maeda, PhD, Professor, Department of Regulatory Science, Meiji Pharmaceutical University
Interviewees:
Korea: Dong-Churl Suh, RPh, MBA, PhD, Professor and Director, College of Pharmacy, Chung-Ang University, Seoul, South Korea
China: Jianwei Xuan, Professor and Director, Health Economics Research Institute, Sun Yat-sen University, Guangzhou, China
This publication represents the consensus opinions of the authors and various members of MAPS but does not represent formal endorsement of conclusions by their organizations.
Introduction
There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for applications including regulatory decisions, health technology assessment (HTA), pharmacovigilance and more. However, Asia currently lacks a framework to effectively collect and utilize a broad range of RWD/RWE[1]. This gap presents Medical Affairs teams with significant opportunity to lead the collection, dissemination and adoption of learnings based on RWE, especially in light of significant market size and burden of diseases such as stroke and ischemic heart disease, which have been the focus on much pharmaceutical development in the West. The objective of this interview-based article is to detail the current state of RWE use in China and Korea and explore what the future evolution will be for its use.
